No clinically significant pharmacokinetic interaction appears to occur between
ganciclovir and
mycophenolate. However, the manufacturers say that in
renal impairment there may be competition for tubular secretion and increased concentra- tions of both drugs may occur. There are reports of
neutropenia in patients taking
mycophenolate with
ganciclovir.
No action is needed, but increased monitoring may be prudent in patients with reduced
renal function. Both
mycophenolate mofetil and
ganciclovir and its prodrug, valganciclovir, have the potential to cause
neutropenia and leucopenia, therefore patients should be closely monitored for additive
toxicity.